These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7198935)

  • 41. Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
    Masuda N; Matsui K; Yamamoto N; Nogami T; Nakagawa K; Negoro S; Takeda K; Takifuji N; Yamada M; Kudoh S; Okuda T; Nemoto S; Ogawa K; Myobudani H; Nihira S; Fukuoka M
    Clin Cancer Res; 2000 Jun; 6(6):2288-94. PubMed ID: 10873079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
    Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH
    Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Active transport of methotrexate from cerebrospinal fluid in humans.
    Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
    Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
    Carmichael SJ; Beal J; Day RO; Tett SE
    J Rheumatol; 2002 Oct; 29(10):2077-83. PubMed ID: 12375315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
    Thomson AH; Daly M; Knepil J; Harden P; Symonds P
    Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacokinetics of urinary excretion of methotrexate (MTX) in patients with malignant tumors].
    Skibińska L
    Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):545-8. PubMed ID: 1480527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-dose pharmacokinetic study of 13-cis-retinoic acid in man.
    Besner JG; Leclaire R; Band P; Meloche S; Deschamps M; Mailhot S; Moisan R; Diorio G
    Cancer Treat Rep; 1985 Mar; 69(3):275-7. PubMed ID: 3856478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck.
    Lustig RA; DeMare PA; Kramer S
    Cancer; 1976 Jun; 37(6):2703-8. PubMed ID: 949688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
    Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
    Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-dependent metabolism of methotrexate in man and rhesus monkeys.
    Jacobs SA; Stoller RG; Chabner BA; Johns DG
    Cancer Treat Rep; 1977 Jul; 61(4):651-6. PubMed ID: 406997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy in head and neck cancer.
    Sullivan RD
    JAMA; 1971 Jul; 217(4):461-2. PubMed ID: 4103928
    [No Abstract]   [Full Text] [Related]  

  • 54. Thirty-six-hour preoperative high-dose methotrexate infusion in patients with squamous carcinoma of the head and neck.
    Hande KR; Chretien PB; Elias EG; Goldberg NH; Brooks AE; Chabner BA
    Med Pediatr Oncol; 1979; 6(1):39-45. PubMed ID: 440204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis.
    Furst DE
    J Rheumatol Suppl; 1985 Dec; 12 Suppl 12():11-4. PubMed ID: 3913770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical use of high dose methotrexate within the Queensland Radium Institute.
    Bourne RG
    Clin Exp Pharmacol Physiol Suppl; 1979; 5():5-9. PubMed ID: 95695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum.
    Haim N; Kedar A; Robinson E
    Cancer Chemother Pharmacol; 1984; 13(3):223-5. PubMed ID: 6541532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate.
    Schifeling DJ; George T; McGuirt F; Capizzi RL; Kamen BA
    Med Pediatr Oncol; 1994; 22(2):88-90. PubMed ID: 8259106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Use of high doses of methotrexate in face and neck epithelial tumors].
    Perlado F; Mateo Ruíz P; Zubiri Vidal A
    Actas Dermosifiliogr; 1979; 70(3-4):279-84. PubMed ID: 484296
    [No Abstract]   [Full Text] [Related]  

  • 60. A preliminary report on the suitability of sheep epidermal squamous cell carcinoma as a solid tumor model in the evaluation of intra-arterial methotrexate administration.
    Harker GJ; Stephens FO; Wass J; Zbroja RA; Chick BF; Grace J
    J Surg Oncol; 1986 Jun; 32(2):65-72. PubMed ID: 3724196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.